Orcutt J C, Possin D E, Bunt-Milam A H
Department of ophthalmology, University of Washington, Seattle, 98195.
Exp Eye Res. 1988 Oct;47(4):621-8. doi: 10.1016/0014-4835(88)90099-1.
Retinal ganglion cells incorporate intravitreally injected [3H]leucine into proteins that are transported orthogradely in optic axons to the superior colliculus. Since optic projections in the albino rabbit are nearly totally crossed, an agent suspected to alter axonal transport can be applied to one optic nerve after bilateral intravitreal injection of [3H]leucine; any reduction in radioactivity transported to the contralateral superior colliculus can then be quantified. Such studies require symmetric uptake and incorporation of precursor into ganglion cell proteins. A technique is described for intravitreal injections that reproducibly produces symmetric uptake of [3H]leucine. Using this technique, we determined that retrobulbar injected lidocaine in clinically used doses (2-4%) does not affect rapid axonal transport, while colchicine (a known inhibitor of axonal transport) blocks transport in a dose-related fashion.
视网膜神经节细胞将玻璃体内注射的[3H]亮氨酸掺入蛋白质中,这些蛋白质沿视神经轴突正向运输至上丘。由于白化兔的视投射几乎完全交叉,在双侧玻璃体内注射[3H]亮氨酸后,可将怀疑改变轴突运输的药物应用于一侧视神经;然后可以对运输到对侧上丘的放射性的任何减少进行量化。此类研究需要前体对称摄取并掺入神经节细胞蛋白质中。本文描述了一种玻璃体内注射技术,该技术可重复性地产生[3H]亮氨酸的对称摄取。使用该技术,我们确定临床使用剂量(2-4%)的球后注射利多卡因不会影响快速轴突运输,而秋水仙碱(一种已知的轴突运输抑制剂)则以剂量相关的方式阻断运输。